From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.

The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.

The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.

At its next meeting, the Australian committee responsible for reviewing the country's health technology assessment system will discuss feedback from stakeholders, including the pharmaceutical industry, on the draft terms of reference for the review.

Last year, the European Commission approved a record 55 therapies containing a new active substance, including 21 medicines for rare diseases. Among them were a number of gene therapies for indications such as cancer and hemophilia.

Pricing challenges, high taxes and the growing problem of drug shortages have led the pharmaceutical industry body Leem to come forward with a set of proposals that it says should inform future government policy towards the sector.